Balancing Trajectory and Velocity: Encouraging Sustainable Growth in Biotech
Summary: In biotech, there鈥檚 a big difference between 鈥渢rajectory鈥 and 鈥渧elocity.鈥 Getting a drug to market quickly, after all, doesn鈥檛 always mean that you鈥檙e on the path to building a sustainable company. For your biotech to thrive over the long term, it鈥檚 critical to continue any forward momentum while ensuring you don鈥檛 run out of fuel halfway through your journey.
But how can an emerging biotech balance both sides for the lasting viability of their business? Read further to hear how Andrew Strong, partner at Pillsbury Winthrop Shaw Pittman LLP, feels about it. Andrew has represented private and public company clients in life sciences, technology, energy, and transportation over the past 25 years.